Description

Risk of bias assessment for randomized controlled trials included in the PRP-FAGA systematic review. Quality evaluation across multiple domains indicates the overall strength of available evidence.

Figure 2

Chart

Source Paper

Investigating the Safety and Efficacy of Platelet-Rich Plasma (PRP) Treatment for Female Androgenetic Alopecia: Review of the Literature.

Medicina (Kaunas, Lithuania) (2021)

PMID: 33806169

DOI: 10.3390/medicina57040311

Cite This Figure

![Figure 2: Risk of bias assessment for randomized controlled trials included in the PRP-FAGA systematic review. Quality evaluation across multiple domains indicates the overall strength of available evidence.]()

> Source: Santo Raffaele Mercuri et al. "Investigating the Safety and Efficacy of Platelet-Rich Plasma (PRP) Treatment fo." *Medicina (Kaunas, Lithuania)*, 2021. PMID: [33806169](https://pubmed.ncbi.nlm.nih.gov/33806169/)

<figure>
  <img src="" alt="Risk of bias assessment for randomized controlled trials included in the PRP-FAGA systematic review. Quality evaluation across multiple domains indicates the overall strength of available evidence." />
  <figcaption>Figure 2. Risk of bias assessment for randomized controlled trials included in the PRP-FAGA systematic review. Quality evaluation across multiple domains indicates the overall strength of available evidence.<br>  Source: Santo Raffaele Mercuri et al. "Investigating the Safety and Efficacy of Platelet-Rich Plasma (PRP) Treatment fo." <em>Medicina (Kaunas, Lithuania)</em>, 2021. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/33806169/">33806169</a></figcaption>
</figure>

Related Evidence

Minoxidil for Androgenetic Alopecia

Grade A · 299 studies

Minoxidil for Female Pattern Hair Loss

Grade A · 111 studies

PRP Therapy for Androgenetic Alopecia

Grade A · 144 studies